The Windsor Framework – what does it mean for life sciences?
For more than two years Northern Ireland has faced difficulties trading with the wider UK. The 2020 Northern Ireland Protocol established systems for trade in and out of Northern Ireland, but has led to a mass of practical difficulties both in the flow of goods across the Irish Sea, and legal compliance for businesses operating […]
For more than two years Northern Ireland has faced difficulties trading with the wider UK. The 2020 Northern Ireland Protocol established systems for trade in and out of Northern Ireland, but has led to a mass of practical difficulties both in the flow of goods across the Irish Sea, and legal compliance for businesses operating in the province. The new Windsor Framework will not please everyone. However, it offers solutions that, if implemented, promise to address many of these problems.
Points to note for the life sciences sector include:
- There will be a move away from the application of EU rules and authorisation requirements for medicines, so that UK law will apply in Northern Ireland and the UK regulator, the MHRA, will be responsible for approval of medicines for the Northern Ireland market.
- The Falsified Medicines Directive will not apply in Northern Ireland.
- Northern Ireland business will still have access to the EU single market where their goods are compliant with EU law.
- Veterinary medicines remain to be addressed, although a grace period for goods from GB to flow into NI lasting until the end of 2025 is planned while a long-term solution is found.
Medical devices do not receive specific attention in the deal, suggesting that there will be no change to the current requirement to follow EU law in the Northern Ireland market. This is disappointing – the existing system is complex and difficult for suppliers to navigate. If the Windsor Framework goes well, however, there might be room for the addition of other product classes like medical devices to its scope.
Finally, unblocking of the Northern Ireland Protocol is expected to lead to progress in other areas. Important here is association to the Horizon Europe programme on scientific collaboration. Stalemate on this issue has been a source of frustration for UK researchers for a long time, and stop gap proposals, although welcome, are considered to fall short of what is needed for innovation to flourish. Hopes are now rising that a breakthrough will soon follow.
More in Science
Fusion technology company Oxford Sigma relocates HQ to Oxford Centre for...
Oxford Sigma has returned to Oxford’s city centre to accelerate fusion materials technology commercialisation to help tackle climate change and resolve energy security, with new global headquarters at The Oxford Trust’s Oxford Centre for Innovation.
Bringing Oxfordshire’s finest together
Intertronics joins B4 as a PLATINUM Member in bid to increase its Oxfordshire network and share expertise with business leaders
Green light for Oxford North’s next three advanced R&D lab buildings...
Detailed designs for three new, prestigious laboratory and office buildings which total 458,100 sq ft (42,549 sq m) and will be built as phase 2 of Oxford North, the new £700 million life sciences innovation district, have been resolved to be approved by Oxford City Council’s planning committee.
From this author
Part 4 of the ‘Fast growth secrets’ series: How to embed customer...
Following our roundtable discussion in Manchester, we explore how fast growth tech businesses can embed the customer and people experience for competitive advantage.
Part 3 of the ‘Fast growth secrets’ series: How to embed ESG...
We held a roundtable discussion to explore the fast-growth secrets of technology businesses and why they should embed ESG into the DNA of their operations.
Part 2 of the ‘Fast growth secrets’ series: The Cambridge and Oxford...
We reveal the fast growth secrets of technology businesses in Cambridge and Oxford.